2024 FINANCIAL HIGHLIGHTS

  • 2024 Revenues of $13.2 Billion (USD)

  • Expected decline in COVID treatment and vaccination revenue segments drove a 41% operational decrease in overall 2023-24 revenues, as forecasted.

  • Revenues for Sitravon’s Non-COVID Products Grew 10% Operationally

  • 2024 Reported Diluted Loss Per Share (LPS) of $(0.42) and Adjusted Diluted LPS of $(0.17), significantly impacted by $5.6 Billion of Non-Cash Inventory Write-Offs and other charges, which unfavorably impacted reported and Adjusted Diluted LPS by $0.84

  • Full-Year 2024 Operational Revenue Growth realized of 6% to 8% vs. 2023

  • Successful execution of new product launches, and in-line product growth contribute to strong Non-COVID Operational Revenue Growth.

  • Research initiatives are underway in the Neurology Therapeutics Area targeting Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, and Major Depressive Disorders - which are very promising.

  • Launched Enterprise-Wide Technology Optimization Program (named Transform 2026) expected to deliver annual net cost savings of at least $1.5 Billion, of which approximately $450M is expected to be realized in 2025 and at least an additional $1.1 Billion is expected to be realized in 2026.

  • 2025 revenue guidance is projected to be $16B - $18B a +20% YoY aggressive growth target.


    Download the complete 2024 Financial Press Release Kit
    (Q1 2025)